Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053522 | 0.75 | SLC1A3 (0.38) | RNPEPCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL6139253 | 0.70 | FOLH1 (0.39) | RNPEPFOLH1ALDH1A1LMNAMAPT | |
| SCHEMBL29377510 | 0.70 | RNPEP (0.33) | RNPEPALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL8880146 | 0.70 | CTSK (0.38) | RNPEPCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL11168976 | 0.69 | SOAT1 (0.42) | FOLH1ALDH1A1LMNA | |
| SCHEMBL16047304 | 0.68 | SLC1A3 (0.33) | RNPEPCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL15992968 | 0.67 | HCAR2 (0.53) | RNPEPCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL16046531 | 0.67 | CACNA2D1 (0.32) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL10802315 | 0.67 | TDP1 (0.40) | RNPEPFOLH1ALDH1A1LMNAMAPT | |
| SCHEMBL16047974 | 0.66 | CTSK (0.33) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| EP-1651643-A4 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC (BM) | 2008-10-08 | — | — | EP | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
| EP-1651643-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005011611-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | PDF, FDPS, DCTPP1 | RNPEP 1116/4885CACNA2D1 4794/4885CACNB3 4780/4885 |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | PDF, FDPS, DCTPP1 | RNPEP 550/4885CACNA2D1 4833/4885CACNB3 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.